Skip to main content

Table 3 Effects of liguzinediol on hemodynamic parameters in MI rats

From: The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism

Group Dose (mg/kg) LVSP (mmHg) LVEDP (mmHg) +dp/dtmax (mmHg/s) −dp/dtmax (mmHg/s) SBP (mmHg) DBP (mmHg) MAP (mmHg)
Sham 121.52 ± 11.58 12.80 ± 4.36 5486.62 ± 1274.77 − 4514.28 ± 1206.89 127.43 ± 13.73 101.40 ± 12.91 110.08 ± 12.24
MI 92.20 ± 9.14** 24.62 ± 11.53** 2879.57 ± 699** − 2602.23 ± 709.79** 94.94 ± 14.45** 68.32 ± 9.91** 77.19 ± 10.94**
Captopril 10 117.70 ± 10.11## 11.07 ± 5.43## 5492.85 ± 1056.12## − 4690.98 ± 407.66## 112.86 ± 14.92#* 83.65 ± 14.24#** 93.38 ± 13.06##**
Digoxin 0.032 107.94 ± 10.11##** 12.82 ± 4.35## 4334.41 ± 805.68##* − 3688.32 ± 679.12## 117.25 ± 14.03## 89.02 ± 14.92## 98.43 ± 13.30##
Liguzinediol 5 112.95 ± 7.67## 14.50 ± 5.08# 4716.70 ± 761.77## − 3902.99 ± 593.81## 117.29 ± 13.67## 86.93 ± 12.69##* 97.05 ± 12.52##*
10 116.26 ± 12.91## 13.77 ± 4.13# 4870.57 ± 839.12## − 4052.40 ± 914.03## 119.43 ± 13.13## 89.17 ± 11.07##* 99.26 ± 11.34##
20 119.48 ± 7.28## 13.47 ± 5.15# 5205.27 ± 968.84## − 4408.84 ± 704.99## 123.03 ± 14.78## 93.47 ± 11.70## 103.32 ± 12.46##
  1. Sham, sham-operated; MI, myocardial infarction; LVSP, LV systolic pressure; LVEDP, LV end-diastolic pressure; +dp/dtmax, maximal rate of the increase of LV pressure; −dp/dtmax, maximal rate of the decrease of LV pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean artery pressure
  2. Data are shown as the mean ± SD (n = 10). *P < 0.05, **P < 0.01, compared to Sham group; #P < 0.05, ##P < 0.01, compared to MI group